Therapeutics/Diagnostics News

The ACG has released a new clinical practice guideline that summarizes therapy options and recommendations for both treatment-naive and treatment-experienced patients with active Helicobacter pylori infection, as well as testing concerns.

Although training primary care providers in shared decision-making did not significantly improve colorectal cancer concordance or screening rates in older adults, at least 5 minutes of discussion with a PCP may benefit some, data showed.

Multidisciplinary care is key when managing patients with pregnancy-related gastrointestinal and liver diseases, with a “paramount goal” of keeping both the patient and the fetus safe, according to an AGA clinical practice update.

Vitamin E improved serum markers of liver inflammation and histology in patients with metabolic dysfunction-associated steatotic liver disease, according to results from a systematic review and meta-analysis.

Although glucagon-like peptide-1 receptor agonist use prior to upper endoscopy was linked to a higher rate of retained gastric contents, evidence supports prolonged fasting as the “optimal approach” rather than routine discontinuation.

Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.

Although evidence suggests the risk for cardiovascular events with small-molecule drugs is low in patients with inflammatory bowel disease, experts advise screening for risk factors and stratification before initiation of therapy.

Vedolizumab not only induced endoscopic improvements in patients with chronic pouchitis, but also appeared to improve clinical outcomes at week 34, especially in those who achieved mucosal healing at week 14, research showed.

A triple therapy of vonoprazan, amoxicillin and bismuth potassium citrate achieved an eradication rate of just over 90%, similar to that of the standard quadruple therapy, in patients with Helicobacter pylori infection, according to data.

Skyrizi significantly improved clinical remission rates as both induction and maintenance therapy vs. placebo in patients with moderately to severely active ulcerative colitis, according to data from the phase 3 INSPIRE and COMMAND trials.